Enzymatic Wound Debridement Market To Reach $1,391.8 Million By 2030

Enzymatic Wound Debridement Market Growth & Trends

The global enzymatic wound debridement market size is expected to reach USD 1,391.8 million by 2030, according to a new report by Grand View Research, Inc., exhibiting a 6.2% CAGR during the forecast period. Introduction of technologically advanced products and rise in incidence of chronic diseases are some of the key factors aiding growth.

Various initiatives are being undertaken by researchers and key players are developing technologically advanced products owing to rising demand for enzymatic wound debridement products globally, which is anticipated to boost market growth. Until now, collagenase-based enzymatic wound debridement products have been majorly used for treatment of chronic & acute wounds and papain-based products have been predominantly used for treatment of chronic wounds. Since awareness about the use of such products is increasing, several technologically advanced products are being introduced in the market. For instance, NexoBrid (NXB), previously referred to as Debriding Gel Dressing (DGD)—which is derived from pineapple Bromelain group of enzymes-was introduced in 2017. NXB is an enzymatic wound debriding drug that can be effectively used in treating deep burn wounds.

The product recently received approval and market players are undertaking initiatives to launch this product under their wound care product portfolio. For instance, in May 2019, Vericel Corporation entered into a supply agreement and exclusive license with MediWound Ltd. with an aim to commercialize the product in North America. The product also received approval in European Union, the U.S., and other international markets. Therefore, such initiatives are anticipated to positively impact growth over the forecast period.

 Request a free sample copy or view report summary: Enzymatic Wound Debridement Market Report

Enzymatic Wound Debridement Market Report Highlights

• In terms of revenue, acute wounds segment held the largest share in 2022 owing to rising trauma cases

• Homecare segment is expected to witness fastest growth rate over the forecast period owing to increasing geriatric population suffering from chronic wounds, who prefer homecare over hospital stay

• Collagenase product segment held the largest share in 2022 due to rising incidence of chronic wounds

• Asia Pacific is expected to witness fastest growth over the forecast period owing to rising number diabetic patients in this region

Enzymatic Wound Debridement Market Segmentation

Grand View Research has segmented the global enzymatic wound debridement market report on the basis of product, type, end-use, and region:

Enzymatic Wound Debridement Type Outlook (Revenue, USD Million, 2018 - 2030)

• Chronic Wounds

  • Diabetic Foot Ulcers

  • Pressure Ulcers

  • Venous Leg Ulcers

• Acute Wounds

  • Burn

  • Other Acute Wounds

Enzymatic Wound Debridement Product Outlook (Revenue, USD Million, 2018 - 2030)

• Collagenase Product

• Papain Product

• Others

Enzymatic Wound Debridement End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Homecare

• Others

Enzymatic Wound Debridement Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Norway

  • Denmark

• Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa

  • Saudi Arabia

  • South Africa

  • UAE

  • Kuwait

List Of Key Players in the Enzymatic Wound Debridement Market

• Convatec Inc.

• Smith & Nephew

• Mölnlycke Health Care AB

• Integra LifeSciences

• SOLASCURE Limited

• B. Braun